vs
阿普塔集团（ATR）与帕兰提尔科技（PLTR）财务数据对比。点击上方公司名可切换其他公司
帕兰提尔科技的季度营收约是阿普塔集团的1.5倍（$1.4B vs $962.7M），帕兰提尔科技净利率更高（43.3% vs 7.7%，领先35.5%），帕兰提尔科技同比增速更快（70.0% vs 13.5%），帕兰提尔科技自由现金流更多（$764.0M vs $96.9M），过去两年帕兰提尔科技的营收复合增速更高（48.9% vs 2.6%）
阿普塔集团（AptarGroup, Inc.）是总部位于美国的全球性制造企业，主营消费品分配包装产品及药物给药装置的研发与生产，目前在全球18个国家设有生产运营基地，服务医药、快消等多领域客户。
帕兰提尔科技是美国上市企业，专注研发数据集成与分析平台，为政府机构、军方及各行业企业提供多源数据整合分析能力。旗下核心产品Gotham与Foundry可打通相互孤立的数据库，广泛支撑情报作业、反恐分析、执法工作及企业级数据分析场景。
ATR vs PLTR — 直观对比
营收规模更大
PLTR
是对方的1.5倍
$962.7M
营收增速更快
PLTR
高出56.5%
13.5%
净利率更高
PLTR
高出35.5%
7.7%
自由现金流更多
PLTR
多$667.1M
$96.9M
两年增速更快
PLTR
近两年复合增速
2.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $962.7M | $1.4B |
| 净利润 | $74.3M | $608.7M |
| 毛利率 | — | 84.6% |
| 营业利润率 | 11.0% | 40.9% |
| 净利率 | 7.7% | 43.3% |
| 营收同比 | 13.5% | 70.0% |
| 净利润同比 | -26.4% | 670.4% |
| 每股收益（稀释后） | $1.13 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ATRPLTR
| Q4 25 | $962.7M | $1.4B | ||
| Q3 25 | $961.1M | $1.2B | ||
| Q2 25 | $966.0M | $1.0B | ||
| Q1 25 | $887.3M | $883.9M | ||
| Q4 24 | $848.1M | $827.5M | ||
| Q3 24 | $909.3M | $725.5M | ||
| Q2 24 | $910.1M | $678.1M | ||
| Q1 24 | $915.4M | $634.3M |
净利润ATRPLTR
| Q4 25 | $74.3M | $608.7M | ||
| Q3 25 | $127.9M | $475.6M | ||
| Q2 25 | $111.7M | $326.7M | ||
| Q1 25 | $78.8M | $214.0M | ||
| Q4 24 | $100.9M | $79.0M | ||
| Q3 24 | $100.0M | $143.5M | ||
| Q2 24 | $90.5M | $134.1M | ||
| Q1 24 | $83.1M | $105.5M |
毛利率ATRPLTR
| Q4 25 | — | 84.6% | ||
| Q3 25 | — | 82.4% | ||
| Q2 25 | — | 80.8% | ||
| Q1 25 | — | 80.4% | ||
| Q4 24 | — | 78.9% | ||
| Q3 24 | — | 79.8% | ||
| Q2 24 | — | 81.0% | ||
| Q1 24 | — | 81.7% |
营业利润率ATRPLTR
| Q4 25 | 11.0% | 40.9% | ||
| Q3 25 | 14.2% | 33.3% | ||
| Q2 25 | 14.9% | 26.8% | ||
| Q1 25 | 12.8% | 19.9% | ||
| Q4 24 | 14.2% | 1.3% | ||
| Q3 24 | 15.2% | 15.6% | ||
| Q2 24 | 13.8% | 15.5% | ||
| Q1 24 | 12.2% | 12.8% |
净利率ATRPLTR
| Q4 25 | 7.7% | 43.3% | ||
| Q3 25 | 13.3% | 40.3% | ||
| Q2 25 | 11.6% | 32.6% | ||
| Q1 25 | 8.9% | 24.2% | ||
| Q4 24 | 11.9% | 9.5% | ||
| Q3 24 | 11.0% | 19.8% | ||
| Q2 24 | 9.9% | 19.8% | ||
| Q1 24 | 9.1% | 16.6% |
每股收益（稀释后）ATRPLTR
| Q4 25 | $1.13 | $0.24 | ||
| Q3 25 | $1.92 | $0.18 | ||
| Q2 25 | $1.67 | $0.13 | ||
| Q1 25 | $1.17 | $0.08 | ||
| Q4 24 | $1.48 | $0.03 | ||
| Q3 24 | $1.48 | $0.06 | ||
| Q2 24 | $1.34 | $0.06 | ||
| Q1 24 | $1.23 | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $409.5M | $7.2B |
| 总债务越低越好 | $1.1B | — |
| 股东权益账面价值 | $2.7B | $7.4B |
| 总资产 | $5.3B | $8.9B |
| 负债/权益比越低杠杆越低 | 0.43× | — |
8季度趋势，按日历期对齐
现金及短期投资ATRPLTR
| Q4 25 | $409.5M | $7.2B | ||
| Q3 25 | $264.8M | $6.4B | ||
| Q2 25 | $169.8M | $6.0B | ||
| Q1 25 | $136.8M | $5.4B | ||
| Q4 24 | $226.2M | $5.2B | ||
| Q3 24 | $327.9M | $4.6B | ||
| Q2 24 | $223.9M | $4.0B | ||
| Q1 24 | $201.1M | $3.9B |
总债务ATRPLTR
| Q4 25 | $1.1B | — | ||
| Q3 25 | $546.0M | — | ||
| Q2 25 | $535.1M | — | ||
| Q1 25 | $561.2M | — | ||
| Q4 24 | $688.1M | — | ||
| Q3 24 | $822.7M | — | ||
| Q2 24 | $681.5M | — | ||
| Q1 24 | $680.4M | — |
股东权益ATRPLTR
| Q4 25 | $2.7B | $7.4B | ||
| Q3 25 | $2.8B | $6.6B | ||
| Q2 25 | $2.7B | $5.9B | ||
| Q1 25 | $2.5B | $5.4B | ||
| Q4 24 | $2.5B | $5.0B | ||
| Q3 24 | $2.5B | $4.5B | ||
| Q2 24 | $2.4B | $4.1B | ||
| Q1 24 | $2.3B | $3.8B |
总资产ATRPLTR
| Q4 25 | $5.3B | $8.9B | ||
| Q3 25 | $5.1B | $8.1B | ||
| Q2 25 | $4.9B | $7.4B | ||
| Q1 25 | $4.5B | $6.7B | ||
| Q4 24 | $4.4B | $6.3B | ||
| Q3 24 | $4.6B | $5.8B | ||
| Q2 24 | $4.5B | $5.2B | ||
| Q1 24 | $4.4B | $4.8B |
负债/权益比ATRPLTR
| Q4 25 | 0.43× | — | ||
| Q3 25 | 0.20× | — | ||
| Q2 25 | 0.20× | — | ||
| Q1 25 | 0.22× | — | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 0.32× | — | ||
| Q2 24 | 0.28× | — | ||
| Q1 24 | 0.29× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $183.7M | $777.3M |
| 自由现金流经营现金流 - 资本支出 | $96.9M | $764.0M |
| 自由现金流率自由现金流/营收 | 10.1% | 54.3% |
| 资本支出强度资本支出/营收 | 9.0% | 0.9% |
| 现金转化率经营现金流/净利润 | 2.47× | 1.28× |
| 过去12个月自由现金流最近4个季度 | $299.6M | $2.1B |
8季度趋势，按日历期对齐
经营现金流ATRPLTR
| Q4 25 | $183.7M | $777.3M | ||
| Q3 25 | $177.6M | $507.7M | ||
| Q2 25 | $126.0M | $539.3M | ||
| Q1 25 | $82.7M | $310.3M | ||
| Q4 24 | $178.2M | $460.3M | ||
| Q3 24 | $229.3M | $419.8M | ||
| Q2 24 | $143.6M | $144.2M | ||
| Q1 24 | $92.3M | $129.6M |
自由现金流ATRPLTR
| Q4 25 | $96.9M | $764.0M | ||
| Q3 25 | $114.3M | $500.9M | ||
| Q2 25 | $62.5M | $531.6M | ||
| Q1 25 | $25.9M | $304.1M | ||
| Q4 24 | $112.2M | $457.2M | ||
| Q3 24 | $162.7M | $415.8M | ||
| Q2 24 | $75.4M | $141.3M | ||
| Q1 24 | $16.7M | $126.9M |
自由现金流率ATRPLTR
| Q4 25 | 10.1% | 54.3% | ||
| Q3 25 | 11.9% | 42.4% | ||
| Q2 25 | 6.5% | 53.0% | ||
| Q1 25 | 2.9% | 34.4% | ||
| Q4 24 | 13.2% | 55.3% | ||
| Q3 24 | 17.9% | 57.3% | ||
| Q2 24 | 8.3% | 20.8% | ||
| Q1 24 | 1.8% | 20.0% |
资本支出强度ATRPLTR
| Q4 25 | 9.0% | 0.9% | ||
| Q3 25 | 6.6% | 0.6% | ||
| Q2 25 | 6.6% | 0.8% | ||
| Q1 25 | 6.4% | 0.7% | ||
| Q4 24 | 7.8% | 0.4% | ||
| Q3 24 | 7.3% | 0.5% | ||
| Q2 24 | 7.5% | 0.4% | ||
| Q1 24 | 8.3% | 0.4% |
现金转化率ATRPLTR
| Q4 25 | 2.47× | 1.28× | ||
| Q3 25 | 1.39× | 1.07× | ||
| Q2 25 | 1.13× | 1.65× | ||
| Q1 25 | 1.05× | 1.45× | ||
| Q4 24 | 1.77× | 5.83× | ||
| Q3 24 | 2.29× | 2.92× | ||
| Q2 24 | 1.59× | 1.08× | ||
| Q1 24 | 1.11× | 1.23× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ATR
| Pharma Segment | $833.1M | 87% |
| Other | $129.6M | 13% |
PLTR
| Geographic Concentration Risk | $1.1B | 77% |
| Other | $330.4M | 23% |
